Abstract
Computed tomography (CT) is considered the imaging modality of choice in evaluation of renal lesions. The advantages of magnetic resonance imaging (MRI) compared to CT include superior soft tissue contrast, avoidance of ionizing radiation and iodinated contrast media, and the possibility of performing functional and advanced imaging techniques such as diffusion-weighted (DWI) and perfusion–weighted imaging (PWI). Although the traditional role of MRI in the evaluation of renal mass is primarily that of a problem-solving tool, DWI and PWI are expanding the role of MRI in management of renal cell cancers. DWI and PWI have shown considerable promise not only in renal lesion detection and characterization as benign or malignant, but also in assessment of renal cell cancer subtype and nuclear grade. Furthermore, these techniques have the potential to assist with tailoring patient- and disease-specific management by providing surgical planning in patients with localized renal cell cancer and assessing treatment response in patients with advanced renal cell cancer undergoing targeted chemotherapy.
Similar content being viewed by others
References
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
Kang SK, Kim D, Chandarana H. Contemporary imaging of the renal mass. Curr Urol Rep. 2011;12(1):11–7.
Ho V, Allen S, Hood M, Choyke P. Renal masses: quantitative assessment of enhancement with dynamic MR imaging. Radiology. 2002;224:695–700.
Hecht EM, Israel GM, Krinsky GA, et al. Renal masses: quantitative analysis of enhancement with signal intensity measurements versus qualitative analysis of enhancement with image subtraction for diagnosing malignancy at MR imaging. Radiology. 2004;232:373–8.
Narumi Y, Miyazaki T, Hatanaka Y, et al. MR imaging evaluation of renal carcinoma. Abdom Imaging. 1997;22:216–25.
Huch Böni RA, Debatin JF, Krestin FP. Contrast-enhanced MR imaging of the kidneys and adrenal glands. Magn Reson Imaging Clin North Am. 1996;4:101–31.
Kallman DA, King BF, Hattery RR, et al. Renal vein and inferior vena cava tumor thrombus in renal cell carcinoma: CT, US, MRI and venacavography. J Computer Assist Tomogr. 1992;16(2):240–7.
Choyke PL, Walther MM, Wagner JR, et al. Renal cancer: preoperative evaluation with dual phase three-dimensional MR angiography. Radiology. 1997;205(3):767–71.
Kutikov A, Uzzo RG. The R.E.N.A.L. nephrometry score: a comprehensive standardized system for quantitating renal tumor size, location and depth. J Urol. 2009;182(3):844–53.
Hayn MH, Schwaab T, Underwood W, Kim HL. RENAL nephrometry score predicts surgical outcomes of laparoscopic partial nephrectomy. BJU Int. 2011;108(6):876–81.
Kutikov A, Smaldone MC, Egleston BL, et al. Anatomic features of enhancing renal masses predict malignant and high-grade pathology: a preoperative nomogram using the RENAL nephrometry score. Eur Urol. 2011;60:241–8.
Chandarana H, Taouli B. Diffusion and perfusion imaging of the liver. Eur J Radiol. 2010
Thoeny HC, De Keyzer F. Diffusion-weighted MR imaging of native and transplanted kidneys. Radiology. 2011;259(1):25–38.
Taouli B, Koh DM. Diffusion-weighted MR imaging of the liver. Radiology. 2010;254(1):47–66.
Kim S, Naik M, Sigmund E, Taouli B. Diffusion-weighted MR imaging of the kidneys and the urinary tract. Magn Reson Imaging Clin N Am. 2008;16(4):585–96.
Squillaci E, Manenti G, Di Stefano F, et al. Diffusion-weighted MR imaging in the evaluation of renal tumours. J Exp Clin Cancer Res. 2004;23:39–45.
Cova M, Squillaci E, Stacul F, et al. Diffusion-weighted MRI in the evaluation of renal lesions: preliminary results. Br J Radiol. 2004;77:851–7.
•• Taouli B, Thakur RK, Mannelli L, et al. Renal lesions: characterization with diffusion-weighted imaging versus contrast-enhanced MR imaging. Radiology. 2009;251:398–407. According to this article, DWI can be used to characterize renal lesions; ADC values are significantly lower in renal malignancies than in benign lesions.
Squillaci E, Manenti G, Cova M, et al. Correlation of diffusion-weighted MR imaging with cellularity of renal tumours. Anticancer Res. 2004;24(6):4175–9.
Zhang J, Tehrani YM, Wang L, et al. Renal masses: characterization with diffusion-weighted MR imaging–a preliminary experience. Radiology. 2008;247:458–64.
• Kim S, Jain M, Harris AB, et al. T1 hyperintense renal lesions: characterization with diffusion-weighted MR imaging versus contrast-enhanced MR imaging. Radiology. 2009;251:796–807. DWI is helpful in differentiating benign from malignant T1 hyperintense lesions.
Sandrasegaran K, Sundaram CP, Ramaswamy R, et al. Usefulness of diffusion-weighted imaging in the evaluation of renal masses. Am J Roent. 2010;194:438–45.
•• Wang H, Cheng L, Zhang X, et al. Renal cell carcinoma: diffusion-weighted MR imaging for subtype differentiation at 3.0 T. Radiology. 2010;257:135–43. The authors state that DWI is helpful in differentiating papillary and clear-cell subtype of RCC with high accuracy.
• Rosenkrantz AB, Niver BE, Fitzgerald EF, et al. Utility of the apparent diffusion coefficient for distinguishing clear cell renal cell carcinoma of low and high nuclear grade. Am J Roent. 2010;195:344–51. According to the authors, high nuclear grade clear cell RCCs have lower ADC compared to clear cell RCC of low grade.
Choi H. Response evaluation of gastrointestinal stromal tumors. Oncologist. 2008;13 Suppl 2:4–7.
Smith AD, Shah SN, Rini BI, Lieber ML, Remer EM. Morphology, Attenuation, Size, and Structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy. AJR Am J Roentgenol. 2010;194(6):1470–8.
Padhani AR, Koh DM. Diffusion MR imaging for monitoring of treatment response. MRI Clin N Am. 2011;19:181–209.
Kamel IR, Reyes DK, Liapi E, Bluemke DA, Geschwind JF. Functional MR imaging assessment of tumor response after 90Y microsphere treatment in patients with unresectable hepatocellular carcinoma. J Vasc Interv Radiol. 2007;18:49–56.
Leary A, Pickering LM, Larkin JMG, et al. Quantitative diffusion-weighted (DW) MR imaging of microcapillary perfusion and tissue diffusivity as biomarkers of response of renal cell carcinoma (RCC) to treatment with sunitinib. Presented at the 2011 American Society of Clinical Oncology Annual Meeting. Chicago, Il. J Clin Oncol 2011; 29: supplement abstract TPS154.
Koh DM, Collins DJ, Orton MR. Intravoxel incoherent motion in body diffusion-weighted MRI: reality and challenges. AJR Am J Roentgenol. 2011;196(6):1351–61.
Chandarana H, Lee VS, Hecht E, Taouli B, Sigmund EE. Comparison of biexponential and monoexponential model of diffusion weighted imaging in evaluation of renal lesions: preliminary experience. Invest Radiol. 2011;46(5):285–91.
Le Bihan D, Breton E, Lallemand D, et al. Separation of diffusion and perfusion in intravoxel incoherent motion MR imaging. Radiology. 1988;168:497–505.
Le Bihan D, Breton E, Lallemand D, et al. MR imaging of intravoxel incoherent motions: application to diffusion and perfusion in neurologic disorders. Radiology. 1986;161:401–7.
Hagiwara M, Rusinek H, Lee VS, et al. Advanced liver fibrosis: diagnosis with 3D whole-liver perfusion MR imaging–initial experience. Radiology. 2008;246:926–34.
Bokacheva L, Rusinek H, Zhang JL, Lee VS. Assessment of renal function with dynamic contrast-enhanced MR imaging. Magn Reson Imaging Clin N Am. 2008;16(4):597–611.
Sourbron SP, Buckley DL. On the scope and interpretation of the Tofts models for DCE-MRI. Magn Reson Med. 2011;66(3):735–45.
• Sun MR, Ngo L, Genega EM, Atkins MB, et al. Renal cell carcinoma: dynamic contrast-enhanced MR imaging for differentiation of tumor subtypes—correlation with pathologic findings. Radiology. 2009;250:793–802. This article shows that different enhancement patterns on two–time point dynamic contrast-enhanced MRI allow for differentiation between clear cell, papillary, and chromophobe RCCs.
Scialpi M, Di Maggio A, Midiri M, Loperfido A, Angelelli G, Rotondo A. Small renal masses: assessment of lesion characterization and vascularity on dynamic contrast-enhanced MR imaging with fat suppression. AJR Am J Roentgenol. 2000;175(3):751–7.
• Notohamiprodjo M, Sourbron S, Staehler M, et al. Measuring perfusion and permeability in renal cell carcinoma with dynamic contrast-enhanced MRI: a pilot study. J Magn Reson Imaging. 2010;31(2):490–501. The authors show that perfusion-weighted MRI can provide information regarding tumor blood flow and permeability.
Hillman GG, Singh-Gupta V, Al-Bashir AK, et al. Dynamic contrast-enhanced magnetic resonance imaging of sunitinib-induced vascular changes to schedule chemotherapy in renal cell carcinoma xenograft tumors. Transl Oncol. 2010;3(5):293–306.
Galbraith SM, Maxwell RJ, Lodge MA, et al. Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J Clin Oncol. 2003;21:2831–42.
• Flaherty KT, Rosen MA, Heitjan DF, et al. Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma. Cancer Biol Ther. 2008;7(4):496–501. In this article, the authors state that perfusion-weighted MRI not only can detect changes in tumor vascularity in response to antiangiogenic drugs, but also may be able to identify patients who are most likely to respond.
Disclosures
A. G. Gilet: none; S. K. Kang: none; D. Kim: none. Dr. Hersh Chandarana has received research support from Siemens Health Care.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Gilet, A.G., Kang, S.K., Kim, D. et al. Advanced Renal Mass Imaging: Diffusion and Perfusion MRI. Curr Urol Rep 13, 93–98 (2012). https://doi.org/10.1007/s11934-011-0227-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11934-011-0227-8